Entera Bio Ltd. (ENTX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.49
- As of
Kresmion compiles this page from ENTX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Entera Bio Ltd. (ENTX): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-06.
See the full ENTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ENTX on one page. Preview it with sample data, then open it live with a free account.
Preview the ENTX dossierActive signals for ENTX
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 71.6%, EPS $-0.14 vs $-0.0816 estimate
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 75% of ENTX (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 99% of ENTX (2026Q1)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +338% to ENTX (2026Q1)
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 23.7% - EPS $-0.07 vs $-0.0918 estimate
FREE, NO ACCOUNT
Every signal on ENTX, as it fires
You are seeing 5 of 9 signals recorded on ENTX since 2026-05-29.
The five above landed across 4 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ENTX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP M40527109 · 2026Q2 | $653K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP M40527109 · 2026Q2 | $69K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ENTX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ENTX against its peers
ENTX's operating margin of -27450.0% ranks in the 14th percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | ENTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 42000 USD | 9.7M USD | 32 | 13 |
| Gross margin | 0.0% | n/a | n/a | 2 |
| Operating margin | -27450.0% | -376.9% | 14 | 10 |
| Net margin | -27235.7% | -310.8% | 14 | 10 |
| Return on equity | -87.3% | -50.5% | 23 | 19 |
| 1 year | -7.8% | -23.5% | 63 | 14 |
Peers (20): PRTA, TECX, YDES, CAPR, AUTL, RZLT, DMAC, EPRX, ZURA, ASMB, SPRY, OVID, ARVN, MYGN, NGNE, MPLT, KYTX, OCS, ALT, EDIT. Left out: PRTC (period gap), AGMB (no annual filing), EIKN (no annual filing), TRXB (no annual filing), DRUG (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ENTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ENTX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ENTX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.